Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase

作者：Zhang Daoguang; Debnath Bikash; Yu Shenghui; Sanchez Tino Wilson; Christ Frauke; Liu Yang; Debyser Zeger; Neamati Nouri^*; Zhao Guisen

来源：Bioorganic & Medicinal Chemistry, 2014, 22(19): 5446-5453.

DOI：10.1016/j.bmc.2014.07.036

• HIV-1 integrase inhibitors
• INSTIs
• 5-Hydroxy-6-oxo-1,6-dihydropyrimidine analogues

Raltegravir (RAL) is a first clinically approved integrase (IN) inhibitor for the treatment of HIV but rapid mutation of the virus has led to chemo-resistant strains. Therefore, there is a medical need to develop new IN inhibitors to overcome drug resistance. At present, several IN inhibitors are in different phases of clinical trials and few have been discontinued due to toxicity and lack of efficacy. The development of potent second-generation IN inhibitors with improved safety profiles is key for selecting new clinical candidates. In this article, we report the design and synthesis of potent 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide analogues as second-generation IN inhibitors. These compounds satisfy two structural requirements known for potent inhibition of HIV-1 IN catalysis: a metal chelating moiety and a hydrophobic functionality necessary for selectivity against the strand transfer reaction. Most of the new compounds described herein are potent and selective for the strand transfer reaction and show antiviral activity in cell-based assays. Furthermore, this class of compounds are drug-like and suitable for further optimization and preclinical studies.

• 出版日期2014-10-1
• 单位山东大学